Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab

A 2-year-old patient with a neuroblastoma developed haemolytic uraemic syndrome (HUS) following treatment with cisplatin and carboplatin. Following treatment with eculizumab, there was a substantial improvement in renal function with the recovery of the platelet count and the cessation of haemolysis. Subsequent investigations showed a novel, heterozygous CD46 splice site mutation with reduced peripheral blood neutrophil CD46 expression. Withdrawal of eculizumab was followed by the recurrence of disease activity, which resolved with re-introduction of therapy. Abnormal regulation of complement may be associated with other cases of cisplatin-induced HUS and treatment with eculizumab may be appropriate for other affected individuals.

[1]  L. Rostaing,et al.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[2]  R. Rieben,et al.  Role of complement and perspectives for intervention in ischemia-reperfusion damage , 2012, Annals of medicine.

[3]  K. Dieckmann,et al.  Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. , 2011, Anticancer research.

[4]  V. Frémeaux-Bacchi,et al.  Atypical hemolytic uremic syndrome , 2011, Orphanet journal of rare diseases.

[5]  H. Cook,et al.  The development of atypical hemolytic uremic syndrome depends on complement C5. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  P. Barlow,et al.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. , 2010, Blood.

[7]  G. Remuzzi,et al.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. , 2006, Kidney international.

[8]  J. Zidan,et al.  Nephrotoxicity of Combined Treatment with Cisplatin and Gentamicin in the Guinea Pig: Glomerular Injury Findings , 2002, Ultrastructural pathology.

[9]  C. Czerny,et al.  Chemotherapy-Related Hemolytic-Uremic Syndrome following Treatment of a Carcinoma of the Nasopharynx , 2001, Oncology.

[10]  P. Johnson,et al.  Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumour. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  D. Mevorach,et al.  Complement-dependent Clearance of Apoptotic Cells by Human Macrophages , 1998, The Journal of experimental medicine.

[12]  L. Gordon,et al.  Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 1997, Seminars in hematology.

[13]  C. Canpolat,et al.  Cisplatin‐Associated hemolytic uremic syndrome , 1994, Cancer.

[14]  M. Christian,et al.  Carboplatin‐associated thrombotic microangiopathic hemolytic anemia , 1989, Cancer.

[15]  M. Rudnick,et al.  Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. , 1984, Annals of internal medicine.